Q3 EPS Estimates for Kura Oncology Boosted by HC Wainwright

Key Points

• HC Wainwright raised Kura Oncology’s Q3 2026 EPS estimate to a loss of $0.85 per share from a prior loss estimate of $0.92. The firm projects continued losses through FY2029, though annual losses are expected to narrow.
• Kura’s latest quarterly results exceeded expectations, with a loss of $0.77 per share versus the $0.88 consensus estimate and revenue of $20.87 million versus $20.16 million expected.
• Analyst sentiment remains generally favorable, with the stock carrying a “Moderate Buy” consensus rating and an average price target of $25.62, despite Kura’s ongoing unprofitability and mixed individual forecasts.

Kura Oncology, Inc. (NASDAQ:KURA - Free Report) - Research analysts at HC Wainwright raised their Q3 2026 EPS estimates for shares of Kura Oncology in a research report issued to clients and investors on Thursday, August 13th. HC Wainwright analyst J. Pantginis now expects that the company will earn ($0.85) per share for the quarter, up from their previous estimate of ($0.92). The consensus estimate for Kura Oncology's current full-year earnings is ($3.30) per share. HC Wainwright also issued estimates for Kura Oncology's FY2026 earnings at ($3.39) EPS, FY2027 earnings at ($2.45) EPS, FY2028 earnings at ($2.34) EPS and FY2029 earnings at ($2.16) EPS.

Kura Oncology (NASDAQ:KURA - Get Free Report) last announced its quarterly earnings data on Wednesday, August 12th. The company reported ($0.77) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.88) by $0.11. Kura Oncology had a negative net margin of 384.30% and a negative return on equity of 207.18%. The business had revenue of $20.87 million during the quarter, compared to the consensus estimate of $20.16 million.

A number of other research firms have also recently issued reports on KURA. Wall Street Zen upgraded Kura Oncology from a "strong sell" rating to a "hold" rating in a report on Saturday, May 16th. Jefferies Financial Group set a $24.00 price target on shares of Kura Oncology in a report on Thursday, May 28th. Citizens Jmp reaffirmed a "market outperform" rating and issued a $24.00 price target on shares of Kura Oncology in a research note on Monday, June 15th. CLSA set a $24.00 price objective on shares of Kura Oncology in a research report on Thursday, June 4th. Finally, Weiss Ratings restated a "sell (d-)" rating on shares of Kura Oncology in a research note on Friday, July 17th. Ten analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average target price of $25.62.

Kura Oncology Stock Performance

KURA opened at $10.86 on Monday. The company has a debt-to-equity ratio of 0.12, a quick ratio of 4.71 and a current ratio of 4.73. The stock's 50 day moving average price is $10.22 and its 200-day moving average price is $9.34. Kura Oncology has a one year low of $6.95 and a one year high of $12.49. The stock has a market cap of $964.04 million, a price-to-earnings ratio of -3.22 and a beta of 0.38.

Institutional Investors Weigh In On Kura Oncology

Several hedge funds have recently modified their holdings of the business. Hennion & Walsh Asset Management Inc. grew its position in shares of Kura Oncology by 69.7% in the 2nd quarter. Hennion & Walsh Asset Management Inc. now owns 568,845 shares of the company's stock worth $6,240,000 after buying an additional 233,633 shares during the last quarter. Dimensional Fund Advisors LP boosted its stake in Kura Oncology by 32.3% in the first quarter. Dimensional Fund Advisors LP now owns 1,425,945 shares of the company's stock valued at $11,591,000 after acquiring an additional 348,127 shares in the last quarter. UBS Group AG grew its holdings in Kura Oncology by 118.3% in the fourth quarter. UBS Group AG now owns 1,060,025 shares of the company's stock worth $11,014,000 after purchasing an additional 574,455 shares during the last quarter. Nan Fung Trinity HK Ltd. increased its position in shares of Kura Oncology by 317.9% during the fourth quarter. Nan Fung Trinity HK Ltd. now owns 964,880 shares of the company's stock worth $10,025,000 after purchasing an additional 734,000 shares in the last quarter. Finally, Janney Montgomery Scott LLC lifted its holdings in shares of Kura Oncology by 285.6% during the 1st quarter. Janney Montgomery Scott LLC now owns 158,850 shares of the company's stock valued at $1,291,000 after purchasing an additional 117,650 shares during the last quarter.

Insider Transactions at Kura Oncology

In other Kura Oncology news, insider Mollie Leoni sold 84,929 shares of the firm's stock in a transaction dated Thursday, June 18th. The shares were sold at an average price of $9.82, for a total transaction of $834,002.78. Following the transaction, the insider owned 182,345 shares of the company's stock, valued at approximately $1,790,627.90. This trade represents a 31.78% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. 7.60% of the stock is currently owned by insiders.

Key Headlines Impacting Kura Oncology

Here are the key news stories impacting Kura Oncology this week:

• Positive Sentiment: Quarterly results exceeded expectations: Kura reported a second-quarter loss of $0.77 per share, narrower than the roughly $0.88–$0.89 consensus loss, while revenue of $20.87 million topped estimates of approximately $20.16 million. The earnings beat may have improved sentiment toward the company’s execution. Kura Oncology Q2 earnings report
• Positive Sentiment: Analyst target increased substantially: Wedbush raised its price target from $36 to $38 and maintained an “outperform” rating. The target implies significant potential upside from the recent trading level, supporting bullish investor expectations. Wedbush raises Kura Oncology price target
• Positive Sentiment: Future revenue visibility: Management outlined a potential $90 million–$110 million in collaboration revenue for 2027 and is targeting 2028 topline results from the KOMET-017 study. These milestones could provide catalysts if development and commercial plans remain on track. Kura collaboration revenue and KOMET-017 update
• Neutral Sentiment: Clinical evidence remains under evaluation: Recent coverage examines what Kura’s latest update means for the clinical evidence supporting its pipeline. The implications for valuation depend on the strength and durability of upcoming data. Kura clinical evidence update
• Negative Sentiment: Analyst estimates are not uniformly improving: Brookline Capital Markets reduced its FY2029 EPS forecast to $5.70 from $6.01, while broader coverage describes conflicting analyst sentiment. Kura remains unprofitable, with analysts expecting a full-year loss, which could limit gains if development spending rises or milestones are delayed. Conflicting analyst sentiment on Kura Oncology

About Kura Oncology

Kura Oncology, Inc NASDAQ: KURA is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted oncology therapies. Headquartered in La Jolla, California, the company leverages expertise in molecular biology and precision medicine to identify key drivers of cancer growth and design small-molecule inhibitors that block those pathways. Kura's research platform integrates genomic insights with medicinal chemistry to advance candidates against well-validated targets in solid tumors and hematologic malignancies.

The company's lead clinical candidate, tipifarnib, is a farnesyltransferase inhibitor being evaluated for the treatment of HRAS-mutant head and neck squamous cell carcinoma and various non-small cell lung cancers.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source